Belgian INAMI/RIZIV updated the List of reimbursable implants and medical devices

In July 2020, new material code and related conditions of reimbursement concerning the endoscopic treatment of primary or secondary vesicoureteral reflux were added to the List of reimbursable devices of the Belgian National Institute for Health and Disability Insurance (INAMI-RIZIV).

The device will be reimbursed with a generic tariff (on the lump-sum basis) without registration in the nominative list.

The following material code has been applied:

• 180950 – 180961 “Product based on PPC (polyacrylate-polyalcohol copolymer hydrogel) used as a bulking agent for the endoscopic treatment of primary or secondary vesicoureteral reflux in children up to the age of sixteen whose kidney function is reduced or who have a recurrent infection (per 0.5 ml)” with a tariff of €182,44.

There are specific conditions of reimbursement, provided in paragraph D-§02 of the List of reimbursable implants and medical devices.

See the updated version of the List of the reimbursable devices in French and Dutch here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.